Hormone therapy: a revolution in understanding prostate cancer

被引：4
|
作者：
Arya, Manit [1 ,2 ]
Shergill, Iqbal S.
Grange, Philippe [2 ]
Emberton, Mark
机构：
[1] Univ Coll London Hosp, Dept Urol, Inst Urol, London WC1E 5DB, England
[2] Kings Coll Hosp London, London, England
来源：
LANCET ONCOLOGY | 2008年 / 9卷 / 11期
关键词：
D O I：
10.1016/S1470-2045(08)70282-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1112 / 1112
页数：1
相关论文
共 50 条
  • [21] Cardiovascular effects of hormone therapy for prostate cancer
    Lester, Jason F.
    Mason, Malcolm D.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2015, 7 : 129 - 138
  • [22] Intermittent hormone therapy in nonmetastatic prostate cancer
    Opfermann, Krisha J.
    Lai, Zongshan
    Essenmacher, Lynette
    Bolton, Sue
    Ager, Joel
    Forman, Jeffrey D.
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 138 - 143
  • [23] RADIOTHERAPY COMBINED WITH HORMONE THERAPY FOR PROSTATE CANCER
    TSUYA, A
    KAWAI, T
    FUKUSHIMA, S
    SHIDA, K
    SHIMAZAKI, J
    MATSUMOT.K
    SETO, T
    STRAHLENTHERAPIE, 1974, 148 (01) : 24 - 34
  • [24] Local recurrence of prostate cancer: hormone therapy
    Altwein, J. E.
    Ebert, T.
    UROLOGE, 2006, 45 (10): : 1276 - +
  • [25] Neoadjuvant and adjuvant hormone therapy for prostate cancer
    Zlotta, AR
    Schulman, CC
    WORLD JOURNAL OF UROLOGY, 2000, 18 (03) : 179 - 182
  • [26] INTERMITTENT HORMONE THERAPY IN PATIENTS WITH PROSTATE CANCER
    Alekseyer, B. Ya.
    NYushko, K. M.
    ONKOUROLOGIYA, 2009, 5 (04): : 7 - 12
  • [27] Targeted therapy in hormone refractory prostate cancer
    Burbridge, S.
    Chowdhury, S.
    Harper, P. G.
    TARGETED ONCOLOGY, 2007, 2 (04) : 235 - 240
  • [28] Regulatory history of hormone therapy for prostate cancer
    Fourcroy, J
    MOLECULAR UROLOGY, 1998, 2 (03) : 215 - 220
  • [29] Therapy of hormone-refractory prostate cancer
    Heidenreich, A
    UROLOGE, 2005, 44 (12): : 1481 - 1494
  • [30] Targeted therapy in hormone refractory prostate cancer
    S. Burbridge
    S. Chowdhury
    P. G. Harper
    Targeted Oncology, 2007, 2 : 235 - 240
12345